In vitro effect of fluoroquinolones against Mycobacterium tuberculosis isolates from Agra & Kanpur region of north India

Indian Journal of Medical Research

Volumn 129, Issue 5, 2009, Pages 542-547

  Singh, Mradula ^a   Chauhan, D S ^a   Gupta, Pushpa ^a   Das, R ^a   Srivastava, R K ^a   Upadhyay, Prashant ^a   Singh, Pushpendra ^a   Srivastava, K ^a   Faujdar, Jaya ^a   Jaudaun, G P S ^a   Yadav, V S ^a   Sharma, V D ^a   Venkatesan, K ^a   Sachan, S ^a   Sachan, P ^a   Katoch, K ^a   Katoch, Vishwamohan M ^b  

^a NATIONAL JALMA INSTITUTE FOR LEPROSY AND OTHER MYCOBACTERIAL DISEASES   (India)

^b GOVERNMENT OF INDIA   (India)

Author keywords

Fluoroquinolones; Mycobacterium tuberculosis; Resistance; Sensitivity

Indexed keywords

CIPROFLOXACIN; GATIFLOXACIN; LEVOFLOXACIN; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SPARFLOXACIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GROWTH; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SCREENING; GROWTH INHIBITION; HUMAN; IN VITRO STUDY; INDIA; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN;

DRUG DISCOVERY; FLUOROQUINOLONES; HUMANS; INDIA; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS;

EID: 70349118703     PISSN: 09715916     EISSN: 09715916     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. IUATLD. Tuberculosis. In: Activity Report of the International Union Against Tuberculosis and Lung Disease; 2004. p. 6-7.
2. Espinal MA, Laszlo S, Simonsen L, Boulahbat F, Kim SJ, Reniero A, et al. Global trends in resistance to antituberculosis drugs. N Engl J Med 2001; 344: 1294-303.
3. World Health Organization. The WHO/IUATLD. Global Project on Antituberculosis Drug Resistance Surveillance: Antituberculosis drug resistance in the world. Report No.3. Geneva: Switzerland; 2004. WHO/ CDS/TB/2004.
4. Paramasivan CN, Venkataraman P. Drug resistance in tuberculosis in India. Indian J Med Res 2004; 120: 377-86.
5. Tomioka H, Sato K, Kajitani H, Akaki T, Shishido S. Comparative antimicrobial activities of the newly synthesized quinolone WQ-3034, levofloxacin, sparfloxacin and ciprofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex. Antimicrob Agents Chemother 2000; 44: 283-6.
6. Aubry A, Pan X-S, Fisher LM, Jarlier V, Cambau E. Mycobacterium tuberculosis DNA gyrase: Interaction with quinolones and correlation with antimycobacterial drug activity. Antimicrob Agents Chemother 2004; 48: 1281-8.
7. Jawahar MS, Rahman F. Shortining short course chemotherapy: A randomized clinical trial for treatment of smear positive pulmonary tuberculosis with regimens using ofloxacin in the intensive phase. Indian J Tuberc 2002; 49: 27-38.
8. Vestal AL. In: Procedure for the isolation and identification of mycobacteria. US Department of Health, Education and Welfare Pub no. (CDC) 77 - 8230. Atlanta, Georgia: Centers for Disease Control and Prevention; 1977. p. 15-90.
9. Guillemin I, Jarlier V, Cambau E. Correlation between quinolone susceptibility patterns and sequences in the A and B subunits of DNA gyrase in mycobacteria. Antimicrob Agents Chemother 1998; 42: 2084-8.
10. Jain NK, Surpal BB, Khanna SP, Fatima T. Drug activity of ofloxacin against clinical isolates of Mycobacterium tuberculosis. Indian J Tuberc 1996; 3: 183-6.
11. Rastogi N, Goh KS. In vitro activity of the new difluorinated quinolone sparfloxacin (AT-4140) against Mycobacterium tuberculosis compared with activities of ofloxacin and ciprofloxacin. Antimicrob Agents Chemother 1991; 35: 1933-6.
12. Ruiz-Serrano MJ, Alcala L, Martinez L, Diaz M, Marin M, Gonzalez-Abad MJ, et al. In vitro activities of six fluoroquinolone against 250 clinical isolates of Mycobacterium tuberculosis susceptible or resistant to first line antituberculosis drugs. Antimicrob Agents Chemother 2000; 44: 2567-8.
13. Tomioka H, Sato K, Akaki T, Kajitani H, Kawahara S, Sakatani M. Comparative in vitro antimicrobial activities of the newly synthesized quinolone HSR-903, sitafloxacin (DU-6859a), gatifloxacin (AM-1155) and levofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex. Antimicrob Agents Chemother 1999; 43: 3001-4.
14. Alvirez- Freites EJ, Carter JL, Cynamon MH. In vitro and in vivo activities of gatifloxacin against Mycobacterium tuberculosis. Antimicrob Agents Chemother 2002; 46: 1022-5.
15. Srivastava K, Das R, Sharma VD, Singh D, Singh HB, Katoch VM. Relevance of degree of rifampicin resistance in Mycobacterium tuberculosis. Indian J Med Microbiol 2001; 19: 36-9.
16. Paramsivan CN, Chandrasekaran V, Santha T, Sudarsanam NM, Prabhakar R. Bacteriological investigations for short course chemotherapy under the tuberculosis programme in two districts of India. Tuber Lung Dis 1993; 74: 23-7.
17. Srivastava K, Das R, Jakhmola P, Gupta P, Chauhan DS, Sharma VD, et al. Correlation of mutations detected by INNOLiPA with levels of rifampicin resistance in Mycobacterium tuberculosis. Indian J Med Microbiol 2004; 120: 100-5.
18. Canetti G, Fox W, Khomenko A, Mahler HT, Menon NK, Mitchison DA, et al. Advances in techniques of testing mycobacterial drug sensitivity and the use of sensitivity tests in tuberculosis control programmes. Bull World Health Organ 1969; 41: 21-43.
19. Gupta P, Jadaun GPS, Das R, Gupta UD, Srivastava K, Chauhan A, et al. Simultaneous ethambutol & isoniazid resistance in clinical isolates of Mycobacterium tuberculosis. Indian J Med Res 2006; 123: 125-30.
20. Venkataraman P, Paramasivan CN, Prabhakar R. In vitro activity of ciprofloxacin and ofloxacin against south Indian isolates of Mycobacterium tuberculosis. Indian J Tuberc 1994; 41: 87-90.
21. Sulochana S, Rahman F, Paramasivan CN. In vitro activity of fluoroquinolones against Mycobacterium tuberculosis. J Chemother 2005; 17: 169-73.
22. Collins CH, Uttley AH. In vitro susceptibility of mycobacteria to ciprofloxacin. J Antimicrob Chemother 1985; 16: 575-80.
23. Gay JD, DeYoung DR, Roberts GD. In vitro activities of norfloxacin and ciprofloxacin against Mycobacterium tuberculosis, M. avium complex, M. chelonei, M. fortuitum and M. kansasii. Antimicrob Agents Chemother 1984; 26: 94-6.
24. Heifets LB, Lindholm-Levy PJ. Bacteriostatic and bactericidal activities of ciprofloxacin and ofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex. Tubercle 1987; 68: 267-76.
25. Heifets LB. Qualitative and quantitative drug susceptibility tests in mycobacteriology. Am Rev Respir Dis 1988; 137: 1217-22.
26. Canetti G, Froman S, Grosset J, Handusoy P, Langerova. M, Mahler HT, et al. Mycobacteria laboratory methods for testing drug sensitivity and resistance. Bull World Health Organ 1963; 29: 565-78.
27. Mitchison DA. Drug resistance in tuberculosis. Eur Respir J 2005; 25: 376-9.
28. Kant L. Using fluoroquinolones for shortening SCC. Indian J Tuberc 2002; 49: 123-4.
29. Grimaldo ER, Tupasi TE , Rivera AB, Quelapio Ma ID, Cardano RC, Derilo JO, et al. Increased resistance to ciprofl oxacin and ofl oxacin in multi drug resistant Mycobacterium tuberculosis isolates from patients seen at a tertiary hospital in the Philippines. Int J Tuberc Lung Dis 2001; 5: 546-50.
30. Andersson MI, Mac Gowan AP. Development of quinolones. J Antimicrob Chemother 2003; 51: 1-11.
31. Casal M, Ruiz P, Herreras A, Spanish study group of Mycobacterium tuberculosis resistance. Study of the in vitro susceptibility of Mycobacterium tuberculosis to ofloxacin in Spain. Int J Tuberc Lung Dis 2000; 4: 588-91.
32. Rodriguez JC, Ruiz M, Climent A, Royo G. In vitro activity of four fluoroquinolones against Mycobacterium tuberculosis. Int J Antimicrob Agents 2001; 17: 229-31.
33. Wright DH, Brown GH, Peterson ML, Rotschafer JC. Application of fluoroquinolone pharmacodynamics. J Antimicrob Chemother 2000; 46: 669-83.
34. Lalande V, Truffot-Pernot C, Paccaly-Moulin A, Grosset J, Ji B. Powerful bactericidal activity of sparfl oxacin (AT-4140) against Mycobacterium tuberculosis in mice. Antimicrob Agents Chemother 1993; 37: 407-13.
35. Lubasch A, Erbes R, Mauch H, Lode H. Sparfloxacin in the treatment of drug resistant tuberculosis or intolerance of first line therapy. Eur Respir J 2001; 17: 641-6.
36. Hu Y, Coates ARM, Mitichison DA. Sterilizing activities of fluoquinolones against rifampin-tolerant populations of Mycobacterium tuberculosis. Antimicrob Agents Chemother 2003; 47: 653-7.
37. Hoffner SE, Gezelius L, Olsson-Liljequist B. In vitro activity of fluorinated quinolones and macrolides against drug resistant Mycobacterium tuberculosis. J Antimicrob Chemother 1997; 40: 885-8.
38. Dam T, Isa M, Bose M. Drug-sensitivity profi le of clinical Mycobacterium tuberculosis isolates - a retrospective study from a chest - disease institute in India. J Med Microbiol 2005; 54: 269-71.
39. Ji B, Lounis N, Truffot-Pernot C, Grosset J. In vitro and in vivo activities of levofl oxacin against Mycobacterium tuberculosis. Antimicrob Agents Chemother 1995; 39: 1341-4.
40. Yoshimatsu T, Nuermberger E, Tyagi S, Chaisson R, Bishai W, Grosset J. Bactericidal activity of increasing daily and weekly doses of moxifl oxacin in murine tuberculosis. Antimicrob Agents Chemother 2002; 46: 1875-9.